From left: Steven Baker, Ph.D., electrical engineer and adjunct research professor of emergency medicine in the OHSU School of Medicine, Bonnie Nagel, Ph.D., professor of psychiatry in the OHSU School of Medicine and associate vice president for research at OHSU, and David Sheridan, M.D. They have teamed up with the semiconductor company Analog Devices, Inc., to use smartwatch technology to collect advanced physiologic data. (OHSU/Christine Torres Hicks)

Oregon Health & Science University biomedical scientist Peter G. Jacobs, Ph.D., secord from left, and OHSU endocrinologist Leah M. Wilson, M.D., left, are leading a new clinical trial that will evaluate how well people with type 1 diabetes can manage their blood sugar levels with the help of OHSU’s artificial intelligence-powered DailyDose smartphone app as well as professionals who specialize in diabetes education or behavioral health. (OHSU/Christine Torres Hicks)

Pictured here is the DailyDose app being displayed on a smartphone and the related diabetes tools with which it works: a glucose sensor transmitter and a smart insulin pen. (OHSU/Christine Torres Hicks)

Pictured here are OHSU staff involved in developing the DailyDose app and organizing the clinical trial, from left: endocrinologist Leah M. Wilson, M.D., diabetes research assistant Deborah L. Branigan, biomedical engineer Clara Mosquera-Lopez, Ph.D., and  scientist Peter G. Jacobs, Ph.D. (OHSU/Christine Torres Hicks)

Pictured here is the DailyDose app being displayed on a smartphone and the related diabetes tools with which it works: a glucose sensor transmitter and a smart insulin pen. (OHSU/Christine Torres Hicks)

Oregon Health & Science University’s Casey Eye Institute clinicians provide Luxturna, an FDA-approved gene therapy to correct blindness-causing mutations to the RPE65 gene, during a Sept. 17, 2018, surgery. Today, OHSU and Oregon State University researchers are developing a new approach to gene therapy that uses lipid nanoparticles to deliver messenger ribonucleic acid, or mRNA, inside the eye. (OHSU/Kristyna Wentz-Graff)

Oregon Health & Science University’s Casey Eye Institute clinicians provide Luxturna, an FDA-approved gene therapy to correct blindness-causing mutations to the RPE65 gene, during a Sept. 17, 2018, surgery. Today, OHSU and Oregon State University researchers are developing a new approach to gene therapy that uses lipid nanoparticles to deliver messenger ribonucleic acid, or mRNA, inside the eye. (OHSU/Kristyna Wentz-Graff)